CCM
PSTX

CAAS Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

CAAS Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-25,000
Closed -$222K – 939
2020
Q3 		$222K Buy
+25,000
New +$284K 0.01% 436

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAAS Capital Management's PSTX Position: Q4 2020 in Review

CAAS Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2020, closing a stake of 25,000 shares — an estimated $222K sold.

CAAS Capital Management first reported a position in PSTX in Q3 2020 and held it in 1 quarter. The position peaked at $222K in Q3 2020. 56 funds tracked by Wall St. Rank hold PSTX as of Q4 2020.

  • CAAS Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • CAAS Capital Management sold 25,000 Poseida Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $222K.
  • CAAS Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • CAAS Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $222K in Q3 2020.
  • 56 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2020.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.